

## ALZpath and Siemens Healthineers enhance global access to blood-based Alzheimer's Disease diagnostic testing

16 December 2025 | News

**Siemens Healthineers will utilise ALZpath's high-performing, proprietary pTau217 antibody in its growing test menu for its Atellica analysers**



US-based ALZpath, Inc., a leading developer of innovative diagnostic tools for Alzheimer's disease and related dementias, has announced a licensing agreement with Siemens Healthineers for use of its proprietary pTau217 antibody in the development of a pTau217 assay in the expanding menu of Siemens Healthineers *in vitro* diagnostic (IVD) tests for Alzheimer's disease. The test is being designed for use on Siemens Healthineers' Atellica immunoassay systems.

Blood-based neurodegenerative disease diagnostics, including those for Alzheimer's, are a transformative advancement. The ALZpath pTau217 antibody has shown exceptional performance across a range of platforms to help identify patients with Alzheimer's disease through a simple blood draw.

It enables sensitive, accurate detection of Alzheimer's disease pathology with performance comparable to PET imaging and cerebrospinal fluid (CSF) testing—and, via *in vitro* diagnostic tests, it may be deployed in a wide range of clinical settings. ALZpath's pTau217 antibody is supported by robust clinical evidence, including more than 90 peer-reviewed studies.

As disease-modifying therapies reach broader use, scalable and accessible diagnostic tools are helping identify patients earlier in their disease. Siemens Healthineers offers integrated immunoassay and clinical chemistry analyzers used in clinical laboratories of all sizes across the world to test patient samples. The unique engineering of the Atellica analyzers maximizes assay precision while also providing industry-leading throughput to materialize test results faster for patients.

"Collaboration drives innovation and advances patient care. The sooner we detect degenerative diseases, the more time clinicians, patients, and families have to prepare—and the more impactful disease modifying therapies can be," said Dirk Heckel, chief technology officer and head of research, development & innovation for Diagnostics at Siemens Healthineers.